Related Experiment Videos
Pathophysiology of renal fluid retention
R W Schrier1, R G Fassett, M Ohara
1Department of Medicine, University of Colorado School of Medicine, Denver 80262, USA. Robert.Schrier@UCHSC.edu
Kidney International. Supplement
|September 15, 1998
Summary
Arginine vasopressin (AVP) causes water retention in conditions like heart failure, cirrhosis, and pregnancy. V2 receptor antagonists effectively reverse this water retention by targeting AVP-mediated aquaporin-2 channels.
Area of Science:
- Physiology
- Nephrology
- Endocrinology
Background:
- Body fluid regulation relies on arterial circulatory integrity.
- Arterial underfilling, from reduced cardiac output or vasodilation, disrupts fluid balance.
- Nonosmotic release of arginine vasopressin (AVP) is stimulated in conditions like cardiac failure (CF).
Purpose of the Study:
- To investigate the role of AVP in body fluid regulation across different physiological and pathological states.
- To evaluate the efficacy of V2 AVP receptor antagonists in managing water retention.
- To explore the mechanism of AVP-mediated water retention involving aquaporin-2 (AQP-2) channels.
Main Methods:
- Utilized V2 AVP receptor antagonists in rat models of low-output CF and cirrhosis.
- Assessed effects on water excretion, solute free water clearance, and AQP-2 expression.
- Studied AVP levels and AQP-2 regulation in normal pregnancy models.
Main Results:
- V2 antagonists corrected impaired water excretion and hyponatremia in CF patients.
- These antagonists increased free water clearance and normalized AQP-2 in CF rats.
- V2 antagonists reversed AVP-mediated water retention and down-regulated AQP-2 in cirrhosis and pregnancy models.
Conclusions:
- AVP-mediated water retention via AQP-2 channels is crucial in low-output CF, cirrhosis, and pregnancy.
- V2 receptor antagonists represent a potential therapeutic strategy for managing fluid imbalances in these conditions.
- Targeting AVP and AQP-2 offers a unified approach to body fluid regulation.